Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) just unveiled an announcement.
Zai Lab Limited announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission. The filing, accessible via the SEC’s website and the company’s own site, fulfills key regulatory disclosure obligations for its U.S.-listed securities and provides shareholders and analysts with detailed financial and operational information for the period.
The company also confirmed its current board composition, led by founder Samantha Du as director, chairperson and chief executive officer, alongside a slate of independent directors. This disclosure underscores Zai Lab’s adherence to corporate governance standards across its Hong Kong and U.S. listings, reinforcing transparency and oversight for its global investor base.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, with principal executive offices in Shanghai and Cambridge, Massachusetts. Its securities include American Depositary Shares listed on the Nasdaq Global Market under the symbol ZLAB and ordinary shares listed on the Stock Exchange of Hong Kong, reflecting a dual-market presence aimed at global investors.
Average Trading Volume: 10,148,595
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.89B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.